New Drug Pricing Plan Ties U.S. Costs to Global Benchmarks
Click to Enlarge
President Trump has issued a new executive order to reduce U.S. drug costs by tying prescription prices to those paid in other developed countries—a concept known as “most-favored-nation pricing”. The order also proposes direct-to-consumer sales for qualifying drugs and measures to limit the role of pharmacy benefit managers (PBMs), which have long been criticized for inflating prices and obstructing physician-prescribed treatments. The administration claims certain drug prices could fall by up to 90%, though legal and logistical challenges remain.
MSSNY believes in patients’ access to affordable medications and has long advocated for similar reforms to address PBM overreach. Policy 110.982 supports reducing healthcare costs by increasing patient access to necessary medications and minimizing PBM interference, while Policy 70.959 explicitly advocates for legislation to prevent PBMs from overriding physician-prescribed dosages and financially coercing patients into formulary switches. These principles also align with MSSNY’s broader efforts to support physician autonomy, reduce administrative burdens, and preserve patient access to affordable care.
Trump Strategy to Rein in Drug Prices Revives ‘Most Favored Nation’ Plan of His First Term (Vinluan, MedCityNews, 5/12).
